Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

regeneron pharmaceuticals inc. - REGN

REGN

Close Chg Chg %
640.14 -4.31 -0.67%

Pre-Market

635.83

-4.31 (0.67%)

Volume: 811.47K

Last Updated:

Mar 27, 2025, 4:00 PM EDT

Trade Now

Company Overview: regeneron pharmaceuticals inc. - REGN

REGN Key Data

Open

$641.21

 Day Range

629.94 - 643.43

52 Week Range

629.02 - 1,211.20

 Market Cap

$69.98B

Shares Outstanding

109.33M

 Public Float

105.40M

Beta

0.27

 Rev. Per Employee

N/A

P/E Ratio

16.54

 EPS

$40.88

Yield

13.88%

 Dividend

$0.88

EX-DIVIDEND DATE

Feb 20, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.00M

  

REGN Performance

1 Week
 
 -3.44%
 
1 Month
 
 -9.00%
 
3 Months
 
 -10.75%
 
1 Year
 
 -33.94%
 
5 Years
 
 41.45%
 

REGN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 28
Full Ratings ➔

About regeneron pharmaceuticals inc. - REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

REGN At a Glance

Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591-6707
Phone 1-914-847-7000 Revenue 14.20B
Industry Pharmaceuticals: Major Net Income 4.41B
Sector Health Technology 2024 Sales Growth 8.27%
Fiscal Year-end 12 / 2025 Employees 15,106
View SEC Filings

REGN Valuation

P/E Current 16.541
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 18.581
Price to Sales Ratio 5.773
Price to Book Ratio 2.66
Price to Cash Flow Ratio 18.548
Enterprise Value to EBITDA 16.302
Enterprise Value to Sales 5.345
Total Debt to Enterprise Value 0.039

REGN Efficiency

Revenue/Employee 940,156.229
Income Per Employee 292,109.096
Receivables Turnover 2.286
Total Asset Turnover 0.40

REGN Liquidity

Current Ratio 4.731
Quick Ratio 3.948
Cash Ratio 2.285

REGN Profitability

Gross Margin 82.739
Operating Margin 29.389
Pretax Margin 33.657
Net Margin 31.07
Return on Assets 12.433
Return on Equity 15.951
Return on Total Capital 13.665
Return on Invested Capital 14.482

REGN Capital Structure

Total Debt to Total Equity 10.012
Total Debt to Total Capital 9.101
Total Debt to Total Assets 7.764
Long-Term Debt to Equity 9.908
Long-Term Debt to Total Capital 9.007
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Regeneron Pharmaceuticals Inc. - REGN

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
16.07B 12.17B 13.12B 14.20B
Sales Growth
+89.14% -24.26% +7.76% +8.27%
Cost of Goods Sold (COGS) incl D&A
2.72B 1.71B 2.24B 2.45B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
286.20M 341.40M 421.00M 482.90M
Depreciation
286.20M 303.80M 328.80M 354.00M
Amortization of Intangibles
- 37.60M 92.20M 128.90M
COGS Growth
+100.89% -37.39% +31.63% +9.22%
Gross Income
13.35B 10.47B 10.87B 11.75B
Gross Income Growth
+86.91% -21.58% +3.87% +8.07%
Gross Profit Margin
+83.05% +85.99% +82.89% +82.74%
2021 2022 2023 2024 5-year trend
SG&A Expense
4.45B 5.17B 6.53B 7.52B
Research & Development
2.62B 3.06B 3.99B 4.62B
Other SG&A
1.82B 2.12B 2.54B 2.90B
SGA Growth
+15.65% +16.31% +26.18% +15.28%
Other Operating Expense
(45.60M) (89.90M) (2.10M) 53.40M
Unusual Expense
(386.10M) 686.50M 539.30M 65.40M
EBIT after Unusual Expense
9.33B 4.70B 3.81B 4.11B
Non Operating Income/Expense
50.20M 219.10M 463.00M 726.70M
Non-Operating Interest Income
- 160.10M 495.90M 711.40M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
57.30M 59.40M 73.00M 55.20M
Interest Expense Growth
+0.70% +3.66% +22.90% -24.38%
Gross Interest Expense
57.30M 59.40M 73.00M 55.20M
Interest Capitalized
- - - -
-
Pretax Income
9.33B 4.86B 4.20B 4.78B
Pretax Income Growth
+144.75% -47.90% -13.57% +13.83%
Pretax Margin
+58.03% +39.91% +32.01% +33.66%
Income Tax
1.25B 520.40M 245.70M 367.30M
Income Tax - Current - Domestic
1.44B 975.90M 675.60M 1.08B
Income Tax - Current - Foreign
(38.40M) 290.90M 407.90M 43.10M
Income Tax - Deferred - Domestic
(423.80M) (800.40M) (841.00M) (940.40M)
Income Tax - Deferred - Foreign
276.70M 54.00M 3.20M 183.10M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
8.08B 4.34B 3.95B 4.41B
Minority Interest Expense
- - - -
-
Net Income
8.08B 4.34B 3.95B 4.41B
Net Income Growth
+129.86% -46.28% -8.87% +11.61%
Net Margin Growth
+50.25% +35.64% +30.14% +31.07%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
8.08B 4.34B 3.95B 4.41B
Preferred Dividends
- - - -
-
Net Income Available to Common
8.08B 4.34B 3.95B 4.41B
EPS (Basic)
76.3983 40.5079 37.0534 40.8953
EPS (Basic) Growth
+133.99% -46.98% -8.53% +10.37%
Basic Shares Outstanding
105.70M 107.10M 106.70M 107.90M
EPS (Diluted)
71.9724 38.2238 34.7722 38.3371
EPS (Diluted) Growth
+135.80% -46.89% -9.03% +10.25%
Diluted Shares Outstanding
112.20M 113.50M 113.70M 115.10M
EBITDA
9.23B 5.73B 4.77B 4.66B
EBITDA Growth
+142.18% -37.97% -16.72% -2.37%
EBITDA Margin
+57.45% +47.05% +36.36% +32.79%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 944.045
Number of Ratings 28 Current Quarters Estimate 9.324
FY Report Date 03 / 2025 Current Year's Estimate 42.203
Last Quarter’s Earnings 12.07 Median PE on CY Estimate N/A
Year Ago Earnings 45.62 Next Fiscal Year Estimate 46.255
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 16 16 22 22
Mean Estimate 9.32 10.45 42.20 46.26
High Estimates 11.15 11.71 47.97 54.68
Low Estimate 7.57 8.69 35.44 36.18
Coefficient of Variance 10.88 8.90 8.34 8.71

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 17 17 19
OVERWEIGHT 2 2 1
HOLD 8 8 8
UNDERWEIGHT 1 1 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Regeneron Pharmaceuticals Inc. - REGN

Date Name Shares Transaction Value
Oct 4, 2024 Arthur Frederick Ryan Director 17,582 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1059.28 per share 18,624,260.96
Oct 4, 2024 Arthur Frederick Ryan Director 17,664 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1044.62 per share 18,452,167.68
Oct 4, 2024 Arthur Frederick Ryan Director 17,657 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1045.27 per share 18,456,332.39
Oct 4, 2024 Arthur Frederick Ryan Director 17,624 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1048.54 per share 18,479,468.96
Oct 4, 2024 Arthur Frederick Ryan Director 17,679 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1041.35 per share 18,410,026.65
Oct 4, 2024 Arthur Frederick Ryan Director 17,678 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1042.31 per share 18,425,956.18
Oct 4, 2024 Arthur Frederick Ryan Director 17,673 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1043.39 per share 18,439,831.47
Oct 4, 2024 Arthur Frederick Ryan Director 17,648 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1046.53 per share 18,469,161.44
Oct 4, 2024 Arthur Frederick Ryan Director 17,615 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1049.68 per share 18,490,113.20
Oct 4, 2024 Arthur Frederick Ryan Director 17,636 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1047.44 per share 18,472,651.84
Oct 4, 2024 Marion McCourt EVP Commercial 7,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 4, 2024 Arthur Frederick Ryan Director 17,609 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1050.6 per share 18,500,015.40
Oct 4, 2024 Marion McCourt EVP Commercial 13,931 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $381.4 per share 5,313,283.40
Oct 4, 2024 Arthur Frederick Ryan Director 17,589 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1054.9 per share 18,554,636.10
Oct 4, 2024 Arthur Frederick Ryan Director 17,586 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1056.68 per share 18,582,774.48
Oct 4, 2024 Marion McCourt EVP Commercial 12,931 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1054.06 per share 13,630,049.86
Oct 4, 2024 Arthur Frederick Ryan Director 17,584 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1057.38 per share 18,592,969.92
Oct 4, 2024 Arthur Frederick Ryan Director 17,592 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1053.45 per share 18,532,292.40
Oct 4, 2024 Arthur Frederick Ryan Director 17,596 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1052.44 per share 18,518,734.24
Oct 4, 2024 Arthur Frederick Ryan Director 17,600 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1051.51 per share 18,506,576.00

Regeneron Pharmaceuticals Inc. in the News